Teva Pharmaceutical Industries annual gross profit
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Gross Profit Growth & History (TEVA)
Teva Pharmaceutical Industries's gross profit was $8.94B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.94B | $874.0M | +10.84% |
| 2024 | 2024-12-31 | $8.06B | $419.0M | +5.48% |
| 2023 | 2023-12-31 | $7.64B | $672.0M | +9.64% |
| 2022 | 2022-12-31 | $6.97B | −$621.0M | −8.18% |
| 2021 | 2021-12-31 | $7.59B | −$132.0M | −1.71% |
| 2020 | 2020-12-31 | $7.73B | $189.0M | +2.51% |
| 2019 | 2019-12-31 | $7.54B | −$759.0M | −9.15% |
| 2018 | 2018-12-31 | $8.30B | −$2.32B | −21.85% |
| 2017 | 2017-12-31 | $10.62B | −$1.04B | −8.91% |
| 2016 | 2016-12-31 | $11.65B | — | — |
| 2013 | 2013-12-31 | $10.71B | $55.0M | +0.52% |
| 2012 | 2012-12-31 | $10.65B | $1.14B | +11.95% |
| 2011 | 2011-12-31 | $9.52B | $450.0M | +4.96% |
| 2010 | 2010-12-31 | $9.06B | $1.70B | +23.05% |
| 2009 | 2009-12-31 | $7.37B | $1.40B | +23.44% |
| 2008 | 2008-12-31 | $5.97B | $1.09B | +22.37% |
| 2007 | 2007-12-31 | $4.88B | — | — |
Teva Pharmaceutical Industries quarterly gross profit
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.15B | $51.0M | +2.43% |
| Q1 2026 | 2026-03-31 | $1.97B | $95.0M | +5.06% |
| Q4 2025 | 2025-12-31 | $2.65B | $534.0M | +25.18% |
| Q3 2025 | 2025-09-30 | $2.30B | $156.0M | +7.26% |
| Q2 2025 | 2025-06-30 | $2.10B | $78.0M | +3.85% |
| Q1 2025 | 2025-03-31 | $1.88B | $106.0M | +5.99% |
| Q4 2024 | 2024-12-31 | $2.12B | −$295.0M | −12.21% |
| Q3 2024 | 2024-09-30 | $2.15B | $297.0M | +16.05% |
| Q2 2024 | 2024-06-30 | $2.02B | $228.0M | +12.69% |
| Q1 2024 | 2024-03-31 | $1.77B | $189.0M | +11.95% |
| Q4 2023 | 2023-12-31 | $2.42B | $646.0M | +36.50% |
| Q3 2023 | 2023-09-30 | $1.85B | $182.0M | +10.90% |
| Q2 2023 | 2023-06-30 | $1.80B | $2.0M | +0.11% |
| Q1 2023 | 2023-03-31 | $1.58B | −$158.0M | −9.08% |
| Q4 2022 | 2022-12-31 | $1.77B | −$279.0M | −13.62% |
| Q3 2022 | 2022-09-30 | $1.67B | −$125.0M | −6.97% |
| Q2 2022 | 2022-06-30 | $1.79B | −$79.0M | −4.22% |
| Q1 2022 | 2022-03-31 | $1.74B | −$138.0M | −7.35% |
| Q4 2021 | 2021-12-31 | $2.05B | $1.0M | +0.05% |
| Q3 2021 | 2021-09-30 | $1.79B | −$58.0M | −3.13% |
| Q2 2021 | 2021-06-30 | $1.87B | $110.0M | +6.24% |
| Q1 2021 | 2021-03-31 | $1.88B | −$185.0M | −8.97% |
| Q4 2020 | 2020-12-31 | $2.05B | $90.0M | +4.60% |
| Q3 2020 | 2020-09-30 | $1.85B | $22.0M | +1.20% |
| Q2 2020 | 2020-06-30 | $1.76B | −$130.0M | −6.87% |
| Q1 2020 | 2020-03-31 | $2.06B | $207.0M | +11.15% |
| Q4 2019 | 2019-12-31 | $1.96B | −$13.0M | −0.66% |
| Q3 2019 | 2019-09-30 | $1.83B | −$147.0M | −7.44% |
| Q2 2019 | 2019-06-30 | $1.89B | −$140.0M | −6.89% |
| Q1 2019 | 2019-03-31 | $1.86B | −$459.0M | −19.83% |
| Q4 2018 | 2018-12-31 | $1.97B | −$473.0M | −19.35% |
| Q3 2018 | 2018-09-30 | $1.98B | −$622.0M | −23.93% |
| Q2 2018 | 2018-06-30 | $2.03B | −$769.0M | −27.44% |
| Q1 2018 | 2018-03-31 | $2.31B | −$455.0M | −16.43% |
| Q4 2017 | 2017-12-31 | $2.44B | −$946.0M | −27.91% |
| Q3 2017 | 2017-09-30 | $2.60B | −$202.0M | −7.21% |
| Q2 2017 | 2017-06-30 | $2.80B | −$75.0M | −2.61% |
| Q1 2017 | 2017-03-31 | $2.77B | −$21.0M | −0.75% |
| Q4 2016 | 2016-12-31 | $3.39B | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $2.80B | $30.0M | +1.08% |
| Q2 2016 · Jun 30 | 2016-06-30 | $2.88B | −$25.0M | −0.86% |
| Q1 2016 · Mar 31 | 2016-03-31 | $2.79B | −$45.0M | −1.59% |
| Q3 2016 · Sep 30 | 2015-09-30 | $2.77B | −$38.0M | −1.35% |
| Q2 2016 · Jun 30 | 2015-06-30 | $2.90B | $241.0M | +9.06% |
| Q1 2016 · Mar 31 | 2015-03-31 | $2.84B | $139.0M | +5.15% |
| Q3 2014 | 2014-09-30 | $2.81B | $179.0M | +6.81% |
| Q2 2014 | 2014-06-30 | $2.66B | $68.0M | +2.62% |
| Q1 2014 | 2014-03-31 | $2.70B | $107.0M | +4.13% |
| Q4 2013 | 2013-12-31 | $2.89B | $109.0M | +3.91% |
| Q3 2013 | 2013-09-30 | $2.63B | $29.0M | +1.11% |
| Q2 2013 | 2013-06-30 | $2.59B | −$64.0M | −2.41% |
| Q1 2013 | 2013-03-31 | $2.59B | −$19.0M | −0.73% |
| Q4 2012 | 2012-12-31 | $2.79B | −$96.0M | −3.33% |
| Q3 2012 | 2012-09-30 | $2.60B | $355.0M | +15.81% |
| Q2 2012 | 2012-06-30 | $2.66B | $457.0M | +20.77% |
| Q1 2012 | 2012-03-31 | $2.61B | $421.0M | +19.24% |
| Q4 2011 | 2011-12-31 | $2.88B | $417.0M | +16.92% |
| Q3 2011 | 2011-09-30 | $2.25B | −$221.0M | −8.96% |
| Q2 2011 | 2011-06-30 | $2.20B | $79.0M | +3.72% |
| Q1 2011 | 2011-03-31 | $2.19B | $175.0M | +8.69% |
| Q4 2010 | 2010-12-31 | $2.46B | $365.0M | +17.39% |
| Q3 2010 | 2010-09-30 | $2.47B | $539.0M | +27.96% |
| Q2 2010 | 2010-06-30 | $2.12B | $352.0M | +19.90% |
| Q1 2010 | 2010-03-31 | $2.01B | $442.0M | +28.13% |
| Q4 2009 | 2009-12-31 | $2.10B | $500.0M | +31.27% |
| Q3 2009 | 2009-09-30 | $1.93B | $436.0M | +29.22% |
| Q2 2009 | 2009-06-30 | $1.77B | $264.0M | +17.54% |
| Q1 2009 | 2009-03-31 | $1.57B | $199.0M | +14.50% |
| Q4 2008 | 2008-12-31 | $1.60B | — | — |
| Q3 2008 | 2008-09-30 | $1.49B | — | — |
| Q2 2008 | 2008-06-30 | $1.50B | — | — |
| Q1 2008 | 2008-03-31 | $1.37B | — | — |
Teva Pharmaceutical Industries gross profit trends
Over the last five fiscal years, Teva Pharmaceutical Industries's gross profit increased from $7.73B to $8.94B, a change of $1.21B. The latest reported quarter, Q2 2026, shows $2.15B.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗